On Thursday, 15 January 2026, Chulabhorn Royal Academy, in collaboration with BeiGene (Thailand) Co., Ltd., organized the 1st Workshop under the project “Improving Access to Immunotherapies while Ensuring Sustainability for the Healthcare System.” The workshop was held at Phra Mae Thorani Rooms 4-5, 1st Floor, Asawin Grand Convention Hotel. The opening ceremony was presided over by Professor Dr. Ruengpung Sutthent, M.D., Acting Deputy Secretary General of Chulabhorn Royal Academy.
The objective of this workshop is to study and estimate the health and economic outcomes of the use of immunotherapy in the treatment of metastatic lung cancer, as well as to explore approaches to enhancing access to immunotherapies for lung cancer treatment within the context of Thailand. The meeting featured panel discussions involving relevant stakeholders, including the National Health Security Office (NHSO), Social Security Office, The Comptroller General’s Department, National Cancer Institute, Department of Medical Services, Health Intervention and Technology Assessment Program (HITAP), medical oncologists, pulmonologists and critical care specialists, as well as academics and researchers.
The outcomes of this workshop are expected to contribute to the development of action plans and collaborative frameworks aimed at genuinely improving patient access to lung cancer treatment, ensuring the fiscal sustainability of healthcare policies, aligning with the Thai healthcare context, and ultimately maximizing benefits for patients.
